4/22/2024

Bumetanide Injection

Products Affected - Description

- Bumetanide injection, Fresenius Kabi, 0.25 mg/mL, 10 mL vial, 10 count, NDC 65219-0570-10
- Bumetanide injection, Fresenius Kabi, 0.25 mg/mL, 4 mL vial, 10 count, NDC 65219-0570-04
- Bumetanide injection, Glenmark, 0.25 mg/mL, 10 mL vial, 10 count, NDC 68462-0470-54
- Bumetanide injection, Glenmark, 0.25 mg/mL, 4 mL vial, 10 count, NDC 68462-0469-54
- Bumetanide injection, Hikma, 0.25 mg/mL, 10 mL vial, 10 count, NDC 00641-6007-10
- Bumetanide injection, Hikma, 0.25 mg/mL, 4 mL vial, 10 count, NDC 00641-6008-10
- Bumetanide injection, Novadoz, 0.25 mg/mL, 10 mL vial, 10 count, NDC 72205-0102-07
- Bumetanide injection, Sagent, 0.25 mg/mL, 10 mL vial, 10 count, NDC 70860-0406-10
- Bumetanide injection, Sagent, 0.25 mg/mL, 4 mL vial, 10 count, NDC 70860-0405-04

Reason for the Shortage

- Fresenius Kabi has bumetanide injection on shortage due to shipping delays.
- Glenmark has bumetanide injection on shortage due to manufacturing delays.
- Hikma has bumetanide injection on shortage due to increased demand.
- Novadoz did not provide a reason for the shortage.
- Pfizer has discontinued bumetanide injection in August 2022.
- Sagent did not provide a reason for the shortage.

Available Products

- Bumetanide injection, Novadoz, 0.25 mg/mL, 4 mL vial, 10 count, NDC 72205-0101-07

Estimated Resupply Dates

- Fresenius Kabi has bumetanide 0.25 mg/mL 4 mL and 10 mL vials on back order and the company estimates a release date of late-May 2024 for the 4 mL vials and mid-May 2024 for the 10 mL vials.
- Hikma has bumetanide 0.25 mg/mL 4 mL vials on back order and the company estimates a release date of late-April 2024. The 10 mL vials are on back order and the company cannot estimate a release date.
- Novadoz has bumetanide 0.25 mg/mL 10 mL vials on allocation.
- Sagent has bumetanide 0.25 mg/mL 4 mL vials available on a limited allocation. The 10 mL vials are on back order and the company estimates a release date of April 2024.
- Glenmark has bumetanide 0.25 mg/mL 4 mL and 10 mL vials on back order and the company estimates a release date of late-May 2024.

Updated

Updated April 22, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created April 23, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.